自4月9日以来，东阳光药(01558)股价持续拉升，5月26日盘中触及15.54港元高点，区间最大涨幅达到 80.70%，并创下近5年以来的股价新高。而这也是市场认可东阳光药创新加速，押注公司未来重磅BD交 易的真实写照。 而就在今年2月，全球制药巨头礼来以7.86亿美元对价与Mediar Therapeutics达成全球许可协议，双方将 携手推进一款针对特发性肺纤维化(IPF)新药的II期临床试验。以上足以看出全球急需疗效更好的IPF新 药。 回到东阳光药，公司的重磅在研新药伊非尼酮之所以值得关注，在于根据此前东阳光披露的信息，体外 及动物体内药效实验证明，伊非尼酮的体外活性是吡非尼酮的200-500倍以上，体内药效作用是吡非尼 酮的40倍，且安全窗高于上市药物。从研发进展来看，其此前中美I期临床已完成，且获得FDA孤儿药 资格认定，II期中期数据则显示其具备潜在"重磅炸弹"属性，目前伊非尼酮的特发性肺纤维化已推进至 临床III期，商业化确定性较高。 值得一提的是，除了特发性肺纤维化外，伊非尼酮亦有间质性肺炎/肝纤维化等大领域可拓展。 药物临床试验登记与信息公示平台显示，除特发性肺纤维化(IPF)外，伊非尼 ...

Group 1 - The core point of the news is that 3SBio has signed a licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707, valued at over $6 billion, setting a record for upfront payments for domestic bispecific antibodies [1] - Following the licensing agreement, 3SBio's stock price surged nearly 40%, pushing its market capitalization above 50 billion RMB, highlighting the growing prominence of domestic innovative drugs in the global market [1] - The trend of Chinese innovative pharmaceutical companies engaging in license-out agreements to share global market benefits has been on the rise, with 2024 expected to see record highs in transaction amounts and events [1] Group 2 - Dongyang Sunshine Pharmaceutical has also engaged in significant licensing agreements, including granting 3SBio exclusive commercialization rights for a specific indication of a drug, showcasing its increasing recognition in the industry [2] - The company has over 100 drugs in development, including 45 first-class innovative drugs, indicating its strong competitive advantage in key research areas [2] - The drug Iphinidone, currently in clinical phase III, shows potential to become a leading treatment for idiopathic pulmonary fibrosis (IPF), a condition with significant unmet medical needs [4] Group 3 - IPF is a chronic and progressive lung disease affecting approximately 3 million people globally, with limited treatment options and poor prognosis, leading to a growing demand for new therapies [3] - Existing treatments like Esbriet and Ofev have demonstrated substantial sales, reflecting the high unmet need in the IPF market [3] - Dongyang Sunshine's Iphinidone has shown superior efficacy compared to existing treatments and is expected to become a significant player in the IPF market, potentially achieving blockbuster status [4]